HLA-B*57:01 Allele Prevalence in HIV-infected North American Subjects and the Impact of Allele Testing on the Incidence of Abacavir-associated Hypersensitivity Reaction in HLA-B*57:01-negative Subjects by Small, Catherine et al.
Touro Scholar 
NYMC Faculty Publications Faculty 
4-1-2017 
HLA-B*57:01 Allele Prevalence in HIV-infected North American 
Subjects and the Impact of Allele Testing on the Incidence of 
Abacavir-associated Hypersensitivity Reaction in HLA-
B*57:01-negative Subjects 
Catherine Small 
New York Medical College 
D Margolis 
M Shaefer 
L Ross 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs 
 Part of the Genetics Commons, and the Virus Diseases Commons 
Recommended Citation 
Small, C., Margolis, D., Shaefer, M., & Ross, L. (2017). HLA-B*57:01 Allele Prevalence in HIV-infected North 
American Subjects and the Impact of Allele Testing on the Incidence of Abacavir-associated 
Hypersensitivity Reaction in HLA-B*57:01-negative Subjects. BMC Infectious Diseases, 17 (1), 256. 
https://doi.org/10.1186/s12879-017-2331-y 
This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for 
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, 
please contact daloia@nymc.edu. 
RESEARCH ARTICLE Open Access
HLA-B*57:01 allele prevalence in HIV-
infected North American subjects and the
impact of allele testing on the incidence of
abacavir-associated hypersensitivity
reaction in HLA-B*57:01-negative subjects
Catherine Butkus Small1,2, David A. Margolis3, Mark S. Shaefer3 and Lisa L. Ross3*
Abstract
Background: The presence of the HLA-B*57:01 allele in HIV-infected subjects is associated with a higher risk of
abacavir-associated hypersensitivity reaction (ABC HSR). HLA-B*57:01 allele prevalence varies in different populations,
but HLA-B*57:01 testing with immunological confirmation has had a negative predictive value for ABC HSR
between 97 and 100%.
Methods: In the ASSURE study (EPZ113734), the HLA-B*57:01 prevalence in virologically suppressed, antiretroviral
treatment–experienced, HIV-infected subjects from the United States, including Puerto Rico, was assessed.
Results: Three hundred eighty-five subjects were screened; 13 were HLA-B*57:01 positive and 372 were negative.
Only HLA-B*57:01-negative, abacavir-naive subjects were eligible to enroll into the ASSURE trial. Eleven of the 13
subjects who possessed the HLA-B*57:01 allele were white, the other 2 were African-American. There was no
geographic clustering of HLA-B*57:01-positive subjects, and the incidence correlated roughly with those states
with the greatest numbers of subjects screened. Similarly, there was no statistically significant correlation between
subjects who possessed or lacked the allele and age, gender, ethnicity or CD4+ T-cell numbers. The incidence
of ABC HSR following abacavir initiation was also evaluated. Only 1 of 199 HLA-B*57:01-negative subjects
(an African-American male) randomized to receive abacavir-containing treatment developed symptoms
consistent with suspected ABC HSR; ABC HSR was not immunologically confirmed.
Conclusions: These findings confirm the utility of HLA-B*57:01 allele testing to reduce the frequency of ABC
HSR. The prevalence of HLA-B*57:01 positivity was higher in white than in African-American subjects. In
HLA-B*57:01-negative subjects, suspected ABC HSR is very rare, but should lead to discontinuation of abacavir
when ABC HSR cannot be definitively excluded from the differential diagnosis.
Trial registration: The ASSURE (EPZ113734) study was registered on ClinicalTrials.gov registration on April 8th
2010 and the registration number is NCT01102972.
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Background
The HLA-B*57:01 allele is associated with a higher risk
of abacavir-associated hypersensitivity reaction (ABC
HSR). This association resulted in a change in treatment
strategies, and independent guidelines now endorse
HLA-B*57:01 screening in HIV-positive patients prior to
initiating ABC-containing regimens [1–3]. Before this
association was determined, ABC HSR rates reported
from clinical studies in which adult HIV-positive sub-
jects were not prospectively tested for the HLA-B*57:01
allele before receiving ABC-containing treatment ranged
from 3 to 6% [4–8]. A review article identified nine cohort
or clinical studies where abacavir was used in HIV-1 in-
fected pediatric patients (only one study included prospect-
ive HLA-B*57:01 at screening), and the pooled incidence
rate of ABC HSR was 2.2% [9]. Several studies conducted
after the association was hypothesized investigated the
positive and negative predictive values of HLA-B*57:01
testing with immunological confirmation by patch testing.
In the Western Australian HIV Cohort study, testing for
the presence of the HLA-B*57:01, HLA-DR7 and HLA-
DQ3 alleles had a positive predictive value for hypersensi-
tivity of 100 and a negative predictive value of 97% [10],
while in the randomized PREDICT-1 study, the presence
of the HLA-B*57:01 allele was associated with a positive
predictive value of 47.9% and a negative predictive value of
100% for immunologically confirmed ABC HSR [5]. In the
US-based SHAPE study, the positive and negative predict-
ive values of HLA-B*57:01 testing were estimated to be 50
and 100%, respectively [6]. In a smaller study conducted in
Spain in which immunological confirmation was not
performed, the positive and negative predictive values were
92 and 63%, respectively [8].
In the first randomized clinical study in the United
States to prospectively screen and enroll only HLA-
B*57:01-negative subjects (ARIES), there was a reported
drop in the incidence of suspected ABC HSR to 0.8% [11].
The current study was the second randomized and con-
trolled US study to prospectively screen and enroll only
HLA-B*57:01-negative subjects. It has been reported in
subsequent studies in which dolutegravir (DTG) has been
used, either in combination with the fixed-dose combin-
ation (FDC) of ABC/lamivudine (3TC) or the FDC of
DTG/ABC/3TC, that hypersensitivity events were ob-
served in less than 1% of treated subjects. However, it was
not possible to determine clinically whether the hypersen-
sitivity reaction was caused by ABC or DTG [12].
The prevalence of this allele varies in different popu-
lations, with whites of European ancestry having higher
frequencies of the HLA-B*57:01 allele than other racial
or ethnic groups, ranging from 5 to 8% [6, 10, 13–16].
In the United States, there is a lower frequency of the
HLA-B*57:01 allele in African Americans, with a reported
frequency between 2.3 and 4% [14, 16].
To further investigate the prevalence of the HLA-
B*57:01 allele in the United States and the impact of
prospective HLA-B*57:01 allele testing on reducing the
incidence of suspected ABC HSR, these factors were
assessed in HIV-infected, virologically suppressed, anti-
retroviral treatment (ART)–experienced subjects from
the United States (including Puerto Rico) who sought to
enroll in the ASSURE study.
Methods
Study design
The ASSURE study (EPZ113734) was an open-label,
multicenter, non-inferiority study in HIV-infected, ART-
experienced subjects. Additional information on the in-
clusion/exclusion criteria, including a link to the study
protocol, is available in a prior publication [17]. Briefly,
HIV-infected subjects from centers in mainland United
States and Puerto Rico were eligible for enrollment if they
were ≥18 years of age, had a confirmed HIV RNA ≤75
copies/ml at screening, and had been on a regimen of
tenofovir/emtricitabine (TDF/FTC; 200-mg/300-mg fixed-
dose tablet; Gilead Sciences, Foster City, California) and
atazanavir/ritonavir (ATV/r; 300-mg tablet of atazanavir
[Bristol Myers Squibb, New York, New York] + 100-mg
tablet of ritonavir [Abbott, Abbott Park, Illinois]) for at
least 6 months immediately prior to study enrollment.
Subjects could have had up to 2 additional prior ART regi-
mens as long as the regimen switch was not due to viro-
logic failure. There were no CD4+ lymphocyte count
restrictions. While a prior HIV genotype was not required,
subjects were ineligible if a prior viral genotype contained
resistance-associated mutations to any study medications.
Subjects were excluded if they were positive for the HLA-
B*57:01 allele or for hepatitis B surface antigen, required
use of prohibited medications, had medical conditions
that could compromise their safety or interfere with drug
absorption, had protocol-specified abnormal laboratory
values, or had a creatinine clearance of <50 mL/min.
Enrolled subjects were randomized 2:1 to receive abaca-
vir/lamivudine (ABC/3TC; 600/300 mg fixed-dose tablet,
ViiV Healthcare, Research Triangle Park, North Carolina)
and 400 mg ATV or to continue TDF/FTC and ATV/r.
All subjects provided written informed consent. The study
received approval by the ethics review boards at each of
the participating centers and was conducted in accordance
with Good Clinical Practice. All of the HLA-B*57:01 test-
ing was performed at Quest Diagnostics (Chantilly, VA)
using the LABType® SSO B kit (ONE LAMBDA,
Canoga Park, CA), which combines Luminex technology
with reverse sequence–specific oligonucleotide DNA typing.
Statistical analysis
The prevalence of suspected ABC HSR was deter-
mined starting at Day 1 for subjects receiving ABC-
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containing ART. Descriptive statistics were primarily used
for data presentation. The Wilcoxon rank sum test and
Fisher’s exact test were used to evaluate study population
differences.
Results
HLA-B*57:01 testing was performed during screening
on 385 HIV-infected subjects from the United States
(including Puerto Rico). The demographics of the
population are shown in Table 1. None of the vari-
ables were statistically significant (P < 0.05) between
the HLA-B*57:01 positive and negative subjects. African-
Americans comprised 35% of the 372 HLA-B*57:01-nega-
tive subjects in the screening population, while the
remaining HLA-B*57:01-negative subjects included 58%
white and 6% Asian subjects. The median CD4 cell count
was somewhat lower for subjects who were HLA-B*57:01-
positive (median 321 cells/mm3) compared with HLA-
B*57:01-negative subjects (482 cells/mm3), however this
difference was not statistically significant (p = 0.0695,
Wilcoxin rank sum test).
Thirteen of the 385 screened subjects (3.4%) were
positive for the HLA-B*57:01 allele. Eleven of these sub-
jects (85%) were white, and the other 2 were African-
American (15%). When categorized by ethnicity, 2 of the
13 patients who were positive for the HLA-B*57:01 allele
were of Hispanic/Latino ethnic background. Due to the
small sample size, the higher prevalence of the HLA-
B*57:01 allele in white subjects was not statistically
significant when compared to other races (P = 0.0827,
2-sided Fisher’s exact test).
To examine whether the prevalence of HLA-
B*57:01-positive subjects was increased in a particular
geographic region, the HLA-B*57:01-positive preva-
lence was compared to the number of subjects
screened within that area (Fig. 1). No geographic
increase was identified, as 11 of the 13 HLA-B*57:01-
positive subjects were from the 5 states with the greatest
numbers of study subjects screened.
Incidence of suspected ABC HSR in HLA-B*57:01-negative
subjects
Two hundred ninety-six subjects met all study eligibility
requirements and were enrolled. Based on the 2:1 study
randomization, 199 subjects initiated ABC/3TC and
ATV therapy, while 99 subjects remained on their pre-
enrollment regimen of TDF/FTC and ATV/r.
Suspected ABC HSR is typically observed shortly after
the initiation of ABC therapy; 93% of these reactions
have been reported to occur during the first 6 weeks of
treatment [4]. During the first 6 months of the ASSURE
study, one of the 199 HLA-B*57:01-negative subjects
randomized to the ABC/3TC + ATV arm developed a
suspected ABC HSR. This subject was a 44-year-old
HLA-B*57:01-negative African-American male who had
met all of the inclusion criteria. One week after starting
ABC/3TC + ATV, the subject developed a rash with
welt-like lesions that increased after taking his antiretro-
viral medications, diarrhea, nausea, headache, and in-
somnia. No liver function test abnormalities or fever
were observed. His signs and symptoms progressed with
continued ART dosing. Concomitant medications in-
cluded enalapril and dapsone, both of which he was
taking for 1 year. At the time of the suspected ABC
HSR, the subject had a non-reactive rapid plasma reagin
(RPR) antigen for syphilis, a negative monospot test, and
a negative test for cytomegalovirus IgM antibody. The
HLA-B*57:01 test was repeated by the same diagnostic
laboratory, and this result confirmed the prior negative
result for the HLA-B*57:01 allele; however, an ABC skin
patch test was not performed. ABC was discontinued
and the prior ART was resumed (TDF/FTC and ATV/r).
The subject’s signs and symptoms resolved within 24 h
after ABC discontinuation. No other cases of suspected
ABC HSR were reported for this study.
Table 1 Demographic comparison of HIV-infected subjects who were positive or negative for the HLA-B*57:01 allele
HIV-1-Infected Subjects Screening Population
HLA-B*57:01 Positive
(n = 13)
Screening Population
HLA-B*57:01 Negative
(n = 372)
Total Enrolled Population
HLA-B*57:01 Negative
(N = 296)
Median Age (range) 42 (26–62) 44 (19–70) 43.5 (20–68)
Male, n (%) 9 (69%) 298 (80%) 234 (79%)
Race
African-American/African Heritage, n (%) 2 (15%) 132 (35%) 102 (34%)
White, n (%) 11 (85%) 216 (58%) 177 (60%)
Asian/Other, n (%) 0 24 (6%) 17 (6%)
Ethnicity
Hispanic/Latino, n (%) 2 (15%) 88 (24%) 77 (26%)
Median CD4 cells/mm3 (range) based on Day 1 values 321 (129–984) 482 (19–1553) 489.5 (77–1479)a
aThis difference was not statistically significant (P = 0.0695, Wilcoxon rank sum test)
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Incidence of study withdrawal due to other adverse
events in HLA-B*57:01-negative subjects
An additional 3 subjects who had been randomized to the
ABC/3TC + ATV treatment group also withdrew during
the first 8 weeks on treatment due to adverse events.
These included 1 subject with urticaria, 1 with mood al-
teration, and 1 with abdominal pain thought to be related
to ABC exposure by the investigator; none demonstrated
signs or symptoms consistent with ABC HSR.
Discussion
Prospective testing for the presence of the HLA-B*57:01
allele was performed for 385 subjects during the screen-
ing procedure for eligibility in the ASSURE Study. As
previously noted, while the association between the
HLA-B*57:01 allele and ABC HSR has been extensively
examined, limited data are available from other large
randomized clinical studies that prospectively tested
for the presence of the HLA-B*57:01 allele prior to
randomization and reported on the frequency of the
allele and its subsequent impact on the incidence of
ABC HSR. The presence of a positive HLA-B*57:01
haplotype was relatively uncommon in this US-based
study, with a total prevalence of 3%, and did not
appear to be geographically clustered but appeared to
be more proportional to the total number of subjects
screened within a particular state.
In the 13 HLA-B*57:01-positive subjects, the preva-
lence of HLA-B*57:01 positivity was higher in white
subjects (although these numbers were too small to
assess significance) at 4.8%, while the frequency of HLA-
B*57:01 positivity was 1.49% for African-Americans. No
Asian subjects tested positive for the HLA-B*57:01 allele
in this study. These HLA-B*57:01-positive frequencies
are similar to those reported by Cao et al., who observed
allele frequencies of 4.15% in whites of European ancestry,
2.3% in African-Americans, and 0.97% in Asian subjects
within the US population [14].
A mechanism of action for ABC HSR has been de-
scribed in which ABC binds to the HLA-B*57:01
antigen-binding cleft, altering its shape and chemistry.
This reaction modifies the peptide loading complex,
generating an array of neopeptides that are antigenic
in nature and drive the T-cell autoimmune responses and
systemic toxicity associated with ABC HSR [16–21].
While these data clearly provide a mechanistic ration-
ale for development of ABC HSR, it cannot be ruled out
that in very rare instances additional immunologic or
toxicological considerations may be relevant for a very
small subset of subjects. In our study, a single instance of
suspected ABC HSR was observed in an HLA-B*57:01-
negative African-American subject. Although the geno-
typic test for the HLA-B*57:01 allele was repeated and
confirmed, a patch test to provide immunological con-
firmation was not performed. A review of the literature
identified 8 additional case reports of suspected ABC HSR
or of symptoms considered by the investigator to be suspi-
cious of HSR in HLA-B*57:01-negative subjects [22–26].
One United Kingdom single site cohort study evaluated
outcomes for 739 HLA-B*57:01 testing results performed
by a single diagnostic testing laboratory and reported that
4 subjects developed symptoms they considered suspi-
cious of HSR despite a negative HLA-B*57:01 result; 2 of
these subjects had ABC skin patch testing performed, and
1 was reported as positive [22]. Of the remaining 4 re-
ported cases, only one subject had ABC skin patch testing
performed with a negative result. A novel in vitro enzyme-
linked immunosorbent spot (ELISPOT) assay has been
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Fig. 1 HLA-B*57:01 prevalence by state within the subject population at the screening visit
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described, which measures cellular in vitro responses to
ABC and might be useful to further characterize suspected
ABC HSR risk in peripheral blood mononuclear cells from
subjects who lack the HLA-B*57:01 allele [27].
Based on the literature, reports of suspected ABC HSR
are extremely rare in HLA-B*57:01-negative patients.
ABC HSR remains a clinical diagnosis and a diagnosis of
possible ABC HSR can be made even when plausible
alternate clinical diagnoses exist. Rash alone without
additional symptoms of a systemic process including
fever, respiratory symptoms, gastrointestinal symptoms,
malaise or myalgias, does not suggest the presence of
underlying ABC HSR. However, patients who develop a
rash after initiating ABC should be closely monitored for
the onset of systemic symptoms. If ABC HSR is suspected,
ABC should be immediately discontinued, with careful
clinical follow-up of the patient [11, 28, 29]. Patients for
whom ABC is stopped should be counseled not to take
ABC-containing products in the future and should dispose
of any remaining ABC-containing products.
Conclusions
The prevalence of HLA-B*57:01 allele in this United
States–based ASSURE study was 3.4%. Prospective
HLA-B*57:01 allele testing with subsequent enroll-
ment of exclusively HLA-B*57:01-negative subjects re-
sulted in a 0.5% incidence of suspected ABC HSR.
These data confirm the utility of HLA-B*57:01 allele test-
ing and the value of prospective screening of patients in
routine clinical practice in preventing ABC HSR and the
associated potential for morbidity and mortality. In HLA-
B*57:01-negative subjects, a diagnosis of suspected ABC
HSR appears to be rare, and a possible mechanism remains
to be elucidated. However, if ABC HSR is suspected, it
should result in discontinuation of ABC.
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